Expired Canadian patentCanada
A combination of candesartan and rosuvastatin for the treatment of atherosclerosis
CA 2540102 C · Owner: Astrazeneca Uk Limited · Inventors: Mehta, Jay Lal
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A combination comprising candesartan and rosuvastatin for the prevention or treatment of arteriosclerosis and for the prevention of cardiovascular events is described.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 22, 2004 and granted July 24, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 22, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 22, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledSeptember 22, 2004
GrantedJuly 24, 2012
Term endedSeptember 22, 2024
Patent numberCA 2540102 C
Classification (IPC)A61K31/50 +1 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.